Management expects operating expenses to rise in 2026 due to substantial investments in sales and technology, which will ...

Guidance shifted from reiterating 2025 revenues above $190 million and adjusted EBITDA above $50 million to projecting 2026 revenues above $190 million and adjusted EBITDA greater than $38 million, ...

(NASDAQ:BTMD) used its fourth-quarter and full-year 2025 earnings call to outline changes made over the past year to its commercial organization and operating model, while also detailing near-term ...

Biote Corp (BTMD) focuses on expanding its sales force and enhancing technology, despite facing revenue and margin pressures.

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

Reports Q3 revenue $51.4M, consensus $51.4M. “Biote’s (BTMD) third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to ...

Operator: Good day, and welcome to the Biote Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that today’s event is being recorded. I would now like to turn the ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ...

Good day, and welcome to the Biote Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. I would now like to turn the conference over ...